Volume 12, Number 2, February 2006

Antimicrobial Drug Resistance, Regulation, and Research

Joshua P. Metlay,*† John H. Powers,‡ Michael N. Dudley,§ Keryn Christiansen,¶ and Roger G. Finch#** on behalf of the Second Colloquium of the International Forum on Antibiotic Resistance
*VA Medical Center, Philadelphia, Pennsylvania, USA; †University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; ‡US Food and Drug Administration, Rockville, Maryland, USA; §Diversa Corporation, San Diego, California, USA; ¶Royal Perth Hospital, Perth, Western Australia, Australia; #Nottingham City Hospital, Nottingham, United Kingdom; and **University of Nottingham, Nottingham, United Kingdom

Figure 3. Relationship between MIC and attainment of the pharmacokinetic/pharmacodynamic (PK/PD) target for effect. Accumulating evidence supports the use of separate PK/PD breakpoints for clinical decision making, distinct from in vitro breakpoints used for epidemiologic surveillance. A breakpoint derived from PK/PD data represents the highest MIC for which the unbound plasma concentrations of the drug (after standard doses) are sufficient to achieve the target PK/PD exposure.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed January 20, 2006

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention